Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
41-60 of 2,251 trials

Hepatocellular Carcinoma: New Vaccine with Atezolizumab and Bevacizumab

We are studying a new cancer vaccine combined with two existing treatments for patients with unresectable liver cancer. The goal is to see if this combination improves survival and quality of life.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHepatologyInternal MedicineOncology

Immunotherapy for Early dMMR Rectal Cancer

We are studying the effects of nivolumab and ipilimumab in patients with stage 1-3 dMMR rectal cancer. The goal is to see how effective and tolerable this treatment is.

Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Oligometastatic Solid Cancer: SBRT with ATRA Support

We are studying a new radiation therapy combined with a drug to support the immune system in patients with oligometastatic solid cancer. This trial aims to evaluate safety and how well the treatment works.

Oligometastatic Solid Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Duchenne Muscular Dystrophy: SQY51 Treatment Study

We are studying the safety and effects of a new treatment called SQY51 in children and adults with Duchenne Muscular Dystrophy. The goal is to see how it impacts muscle function and overall well-being.

Duchenne Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOrthopedics and Traumatology

Post-Cardiac Arrest Shock: High-Dose Vitamin C Study

We are investigating whether early intravenous high-dose vitamin C can help patients who have suffered a cardiac arrest and are in shock. The study aims to see if this treatment reduces the need for blood pressure support and improves survival and recovery.

Cardiac Arrest6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

HER2+ Breast Cancer: Tucatinib with Oral Etoposide and Trastuzumab

We are studying a new treatment combining tucatinib, oral etoposide, and trastuzumab for patients with metastatic HER2+ breast cancer who have not responded to prior therapies. The goal is to see if this combination improves treatment outcomes and safety.

Metastatic HER2+ Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Salivary Duct Carcinoma: Dutasteride with Combined Androgen Blockade

We are studying whether adding dutasteride to standard therapy helps patients with recurrent or metastatic salivary duct carcinoma. The trial also looks at safety and quality of life for those receiving this new treatment.

Salivary Duct CarcinomaEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Heart Attack Treatment: Methylprednisolone Study

We are investigating whether a steroid given before hospital treatment can reduce heart damage in patients with a heart attack. This study aims to improve heart function and decrease inflammation after the event.

Heart Attack1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Advanced Breast Cancer: Ribociclib Study

We are examining how well Ribociclib works for patients with advanced breast cancer and what factors may affect its effectiveness. The study also looks at quality of life and any side effects experienced during treatment.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Hematologic Cancers: Continued Treatment with Tafasitamab

We are providing ongoing treatment for patients with blood cancers who have previously received Tafasitamab. This study focuses on evaluating the safety of continued use of this medication.

Hematological MalignancyConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Morphine Study in Obesity and Sleep Apnea Patients

We are investigating how obesity and obstructive sleep apnea influence the effects of morphine for pain relief. This research aims to improve pain management for patients, especially those having bariatric surgery.

Obesity Surgery>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementEndocrinologyInternal MedicineOrthopedics and TraumatologyOtolaryngologyPsychiatry

Multiple Myeloma: Anti-BCMA CAR T Cell Therapy

We are studying a new CAR T cell treatment for patients with relapsed or refractory Multiple Myeloma. The trial aims to evaluate its safety and effectiveness in improving patient outcomes.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Acute Myeloid Leukemia: New Treatments for Children and Adolescents

We are exploring different therapies for children and adolescents with acute myeloid leukemia to see if they improve survival and treatment outcomes. This includes testing new drugs alongside standard chemotherapy.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyPediatrics

Multiple Myeloma: Linvoseltamab Treatment Study

We are investigating the safety and effectiveness of linvoseltamab in patients with newly diagnosed multiple myeloma who have not yet received treatment. This study will help us understand how well this new therapy works for different patient groups.

Multiple MyelomaEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Advanced Non-Small Cell Lung Cancer: Datopotamab Deruxtecan and Pembrolizumab

We are studying a new treatment combination for patients with advanced non-small cell lung cancer who have not had prior therapy. The goal is to see if this combination works better than standard treatments in improving survival and reducing disease progression.

Advanced Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Arrhythmic Mitral Valve Prolapse: Flecainide and Metoprolol Study

We are studying whether adding flecainide to metoprolol can better reduce irregular heartbeats in patients with arrhythmic mitral valve prolapse. This trial aims to assess the safety and effectiveness of this combination treatment.

Mitral Valve Prolapse>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Prostate Cancer: Neoadjuvant Treatment with [177Lu]Lu-PSMA-617

We are studying a new method of delivering a targeted treatment for men with high-risk prostate cancer before surgery. The goal is to evaluate its safety and how well it works compared to standard approaches.

High-Risk Prostate Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Post-Traumatic Stress Disorder: Testing New Therapy

We are studying a new therapy called reconsolidation therapy for people with severe PTSD. This trial compares it to standard treatment and looks at whether adding propranolol can improve outcomes.

Post-Traumatic Stress Disorder≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Esophageal Cancer Treatment: The NEEDS Trial

We are comparing two treatment methods for operable esophageal squamous cell carcinoma to see which may help patients survive longer. The study also examines quality of life and other health impacts during and after treatment.

Locally Advanced Esophageal Squamous Cell Carcinoma≤3 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology

Melanoma Treatment: Nivolumab + Relatlimab Injection Study

We are comparing a new way to give a combination treatment for advanced melanoma to see if it works as well as the traditional method. This study is for people who have not yet been treated for their melanoma.

Metastatic MelanomaConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology